■ Abstract The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with relapsing multiple sclerosis (MS). Further analyses of AFFIRM and SENTINEL data were conducted to determine the efficacy of natalizumab in prespecified patient subgroups according to baseline characteristics: relapse history 1 year before randomization (1, 2, ≥ 3), Expanded Disability Status Scale score (≤ 3.5, > 3.5), number of T2 lesions (< 9, ≥ 9), presence of gadolinium-enhancing (Gd+) lesions (0, ≥ 1), age (< 40, ≥ 40) and gender (male, female). A post hoc analysis was conducted to determine the efficacy of natalizumab in patients with highly active disease (i. e., ≥ 2 relapses in the year before study entry and ≥ 1 Gd+ lesion at study entry). In both AFFIRM and SENTINEL studies natalizumab reduced the annualized relapse rates across all subgroups (except the small subgroups with < 9 baseline T2 lesions) over 2 years. In AFFIRM, natalizumab significantly reduced the risk of sustained disability progression in most subgroups. In SENTINEL, natalizumab significantly reduced the risk of sustained disability progression in the following subgroups: ≥ 9 T2 lesions at baseline, ≥ 1 Gd+ lesions at baseline, female patients and patients < 40 years of age. Natalizumab reduced the risk of disability progression by 64 % and relapse rate by 81 % in treatment-naïve patients with highly active disease and by 58 % and 76 %, respectively, in patients with highly active disease despite IFNβ-1a treatment. These results indicate that natalizumab is effective in reducing disability progres-
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Introduction
Inflammation, a pathologic hallmark of MS, results from infiltration of the central nervous system (CNS) by leukocytes [1] , which gain access to the CNS by adhering to blood-brain barrier endothelial and glial cells. Binding between these cell types is the result of interactions between the adhesion molecule α4β1 integrin on the surface of leukocytes and vascular cell adhesion molecule (VCAM)-1 present on the surface of endothelial cells [2] [3] [4] . Recurrent infiltration of inflammatory leukocytes and monocytes into the brain and spinal cord results in demyelination and axonal degeneration.
Natalizumab (TYSABRI®, Biogen Idec, Inc. and Elan Pharmaceuticals, Inc.) is a novel selective adhesion molecule inhibitor that blocks the interaction of α4-integrin with VCAM-1. Natalizumab has been shown to reduce the transmigration of lymphocytes into the CNS and to prevent the development of experimental autoimmune encephalomyelitis in animal studies [5] . Following favorable phase 2 studies [6] [7] [8] , a randomized, doubleblind, placebo-controlled phase 3 study of natalizumab monotherapy in relapsing-remitting MS (AFFIRM) demonstrated a reduction of sustained disability progression by 42 % (p < 0.001) and annualized relapse rate by 68 % (p < 0.001) over 2 years compared with placebo [9] . A second phase 3 clinical study (SENTINEL) evaluated the efficacy and safety of natalizumab in combination with interferon beta (IFNβ)-1a (Avonex®, Biogen Idec, Cambridge, MA) [10] in patients who had experienced breakthrough disease activity (≥ 1 relapse in the 12 months prior to randomization) on IFNβ-1a treatment. In SENTINEL, combination therapy with natalizumab and IFNβ-1a reduced the risk of sustained disability progression by 24 % (p = 0.02) and annualized relapse rate by 55 % (p < 0.001) over 2 years compared with IFNβ-1a alone [10] .
Disease activity and severity vary considerably among patients, even in those recruited to phase 3 multicenter studies. Evidence exists that MS is a pathologically heterogeneous disease [11] , meaning patients may respond differently to treatment. The aim of this paper was to examine the question of variable responsiveness to natalizumab therapy by examining its efficacy in prespecified patient subgroups in relation to their prestudy disease activity and demographic characteristics. In addition, post hoc analyses were conducted to evaluate the efficacy of natalizumab in patient subgroups based on gender and in a subgroup of patients with highly active MS.
Methods
Full descriptions of the AFFIRM and SENTINEL study methods have been published [9, 10] . Briefly, 942 men and women 18-50 years of age were enrolled in AFFIRM, and 1,196 men and women 18-55 years of age in SENTINEL. Data from 1,171 patients in SENTINEL were analyzed owing to the fact that before unblinding, a single center that enrolled 25 patients was excluded based on irregularities in the data. All patients in both studies provided written informed consent and had a diagnosis of MS according to McDonald criteria [12] , a baseline Expanded Disability Status Scale (EDSS) score of 0.0-5.0 [13] , a cranial magnetic resonance imaging (MRI) scan demonstrating lesions consistent with MS and at least 1 medically documented relapse within 12 months prior to randomization.
Patients were randomized (2:1 ratio in AFFIRM, 1:1 ratio in SEN-TINEL) to receive natalizumab 300 mg or placebo via intravenous infusion every 4 weeks for up to 116 weeks. All patients in SENTINEL also received IFNβ-1a 30 μg once weekly. At 1 year, the predefined primary endpoint was the rate of clinical relapse and secondary efficacy endpoints included the proportion of relapse-free patients. At 2 years, the predefined primary endpoint was disability progression sustained for 12 weeks as measured by the EDSS, and secondary efficacy endpoints included the rate of clinical relapse.
An analysis was conducted on the effects of natalizumab on both primary and secondary endpoints in prespecified patient subgroups, based on the following baseline and demographic characteristics: number of relapses during the year prior to enrollment (1, 2, ≥ 3), EDSS score (≤ 3.5, > 3.5), number of T2 lesions (< 9, ≥ 9), presence of Gd+ lesions (0, ≥ 1) and age (< 40, ≥ 40). A post hoc analysis of the effects of natalizumab in patient subgroups according to gender was also performed. Selection of these factors was based on natural history data and data analyses of prior studies that showed these variables to be potentially important predictors of clinical outcome [14] [15] [16] [17] . Analyses also were conducted in subgroups of patients with highly active relapsing MS, defined as ≥ 2 relapses in the year prior to study entry and ≥ 1 Gd+ lesion on T1-weighted MRI at study entry.
■ Statistical analysis
Within each of 13 subgroups (number of relapses during the year prior to enrollment [1, 2, ≥ 3] , baseline EDSS score [≤ 3.5, > 3.5], baseline number of T2 lesions [< 9, ≥ 9], baseline presence of Gd+ lesions [0, ≥ 1], age [< 40, ≥ 40] and gender [male, female]), the treatment effect on sustained disability progression, defined as a ≥ 1.0-point increase in EDSS from a baseline EDSS of ≥ 1.0 or as a ≥ 1.5-point increase in EDSS from a baseline EDSS of 0.0 sustained for 12 weeks, was assessed. For patients with highly active disease, EDSS progression as previously defined sustained for 12 and 24 weeks were analyzed. The Cox proportional hazards model was used to compute hazard ratio (HR) and 95 % confidence interval (CI). An adjustment for baseline EDSS and age was made because a backward stepwise selection procedure revealed a statistical association between these factors and the 2-year disability progression endpoint. Cumulative probabilities of disability progression at 2 years were estimated from a Kaplan-Meier analysis and were compared using the proportional hazards model.
Poisson regression was used to calculate the annualized relapse rate and to compute rate ratio (RR). An adjustment for the number of relapses in the year prior to study entry was made. Relapses occurring less than 30 days following the onset of a protocol-defined relapse were considered part of the same relapse, and those occurring after a sion and relapses in patients with relapsing MS, particularly in patients with highly active disease.
■ Key words multiple sclerosis · natalizumab · interferon beta-1a · subgroup analysis · highly active relapsing multiple sclerosis patient received alternative MS medications were excluded from the analysis. A Cox proportional hazards model was used to calculate HR and 95 % CI for cumulative probability of first relapse. An adjustment was made for the number of relapses in the year prior to screening. Cumulative probabilities of relapse at 2 years were estimated from a Kaplan-Meier analysis and were compared using the proportional hazards model.
MRI endpoints (T2-hyperintense, gadolinium-enhancing or T1-hypointense lesions) of treatment groups were compared using logistic regression, adjusting for baseline lesion. The presentation conforms to recently published guidelines on reporting subgroup analyses [18] . A total of 35 significance tests were performed for each of the AFFIRM and SENTINEL studies, including 13 prespecified subgroup analyses for both disability progression and relapse rate and 9 endpoints for the subgroup with highly active disease. Given the number of statistical tests performed in each study, one would anticipate 1−2 to be statistically significant at the p < 0.05 level (Type 1 error) and no more than 1 at the p < 0.001 level.
Results

■ Prespecified subgroups Patient demographics
Of the 942 patients enrolled in AFFIRM, 315 were randomly assigned to the placebo group and 627 to the natalizumab group. In SENTINEL, 1,171 patients were randomized to receive either IFNβ-1a alone (n = 582) or IFNβ-1a plus natalizumab (n = 589). Within each study, no notable differences were observed between the two treatment groups for any demographic or baseline disease characteristics (Table 1) . (28) 211 (67) 104 (33) 442 (75) 147 (25) 420 (72) 162 (28 (2) 19 (3) 11 (3) 6 (2) 9 (3) 589 (100) 57 (10) 26 (4) 582 (100) 54 (9) 27 (5) Baseline EDSS score Mean ± SD ≤ 3.5, n (%) > 3.5, n (%)
2.3 ± 1.2 548 (87) 79 (13) 2.3 ± 1.2 278 (88) 37 (12) 2.4 ± 1.1 508 (86) 81 (14) 2.5 ± 1.1 491 (84) 91 ( (31) 56 (9) 1.5 ± 0.9 6 (2) 180 (57) 102 (32) 27 (9) 1.5 ± 0.8 (66) 153 (26) 44 (8) 1.4 ± 0.8 (30) 50 (9) 1.5 ± 0.7 Number of T2 lesions, n (%) < 9 ≥ 
Sustained disability progression
For the overall AFFIRM study population, the cumulative probability of 12-week sustained disability progression at 2 years was 17 % in the natalizumab group compared with 29 % in the placebo group, representing a 42 % reduction in the risk of sustained disability progression with natalizumab treatment (HR = 0.58; CI: 0.43, 0.77; p < 0.001) [9] . A sensitivity analysis of disability progression sustained for 24 weeks yielded a 54 % risk reduction with natalizumab compared with placebo over 2 years (HR = 0.46; CI: 0.33 to 0.64; p < 0.001). Fig. 1 shows the effects of natalizumab monotherapy on disability progression in each of the prespecified subgroups in AFFIRM. Compared with placebo, natalizumab significantly reduced the risk of disability progression in most subgroups with the exception of the following subgroups: patients with two relapses during the year prior to study enrollment, patients with a baseline EDSS score > 3.5, patients with < 9 T2 lesions, male patients and patients ≥ 40 years of age (Fig. 1 a) .
In the overall SENTINEL study population, patients treated with IFNβ-1a plus natalizumab had a 23 % cumulative probability of 12-week sustained disability progression, compared with 29 % in patients treated with IFNβ-1a alone. This represents a 24 % risk reduction with the addition of natalizumab to the treatment regimen (HR = 0.76; CI: 0.61, 0.96; p = 0.02) [10] . Combined therapy compared with IFNβ-1a alone significantly reduced the risk of progression in subgroups with ≥ 9 T2 lesions at baseline, ≥ 1 Gd+ lesions at baseline, female patients, and patients < 40 years of age (Fig. 1 b) . There were no significant effects in the other subgroups analyzed.
Annualized relapse rate
In the overall AFFIRM study population, natalizumab significantly reduced annualized relapse rate by 68 % over 2 years compared with placebo (0.23 vs. 0.73, p < 0.001) [9] . Fig. 2 a shows the effects of natalizumab monotherapy on relapse rate in each of the prespecified subgroups. Natalizumab reduced the risk of relapse in all subgroups compared with placebo. The treatment effect reached statistical significance in all subgroups except for a small subgroup of patients with < 9 T2 lesions at baseline.
Combination therapy with natalizumab plus IFNβ-1a in SENTINEL significantly reduced the annualized relapse rate for the overall population by 55 % (0.34 vs. 0.75, p < 0.001) over 2 years of treatment compared with IFNβ-1a alone [10] . Fig. 2 b shows the effects of natalizumab plus IFNβ-1a on relapse rate in each of the prespecified subgroups. Similar to results of the AFFIRM subgroup analyses, combination therapy reduced the risk of relapse in all subgroups compared with IFNβ-1a alone, except for the small subgroup of patients with < 9 T2 lesions at baseline.
■ Patients with highly active disease
In the AFFIRM study, 148 natalizumab patients and 61 placebo patients met the criteria for treatment-naïve highly active relapsing MS (≥ 2 relapses in the year prior to study entry and ≥ 1 Gd+ lesion on T1-weighted MRI at study entry). Demographic and disease characteristics were similar between the natalizumab and placebo groups (data not shown). The mean (SD) age was 34.5 (8.42) years, and the median time since diagnosis was 2 years (range, 0-20). Overall, 75 %, 18 % and 7 % of patients experienced 2, 3 and ≥ 4 relapses, respectively, during the year prior to study entry. The median time since last relapse was 4 months in both treatment groups.
In this treatment-naïve AFFIRM population with highly active disease, the 2-year cumulative probability of disability progression sustained for 12 weeks was 14 % in the natalizumab group and 29 % in the placebo group (HR = 0.47; 95 % CI: 0.24, 0.93; p = 0.029), which represents a 53 % reduction with natalizumab therapy. Using a more stringent definition of disability progression, natalizumab reduced the 2-year cumulative probability of disability progression sustained for 24 weeks by 64 % (HR = 0.36; CI: 0.17, 0.76; p = 0.008; Fig. 3 a) . Natalizumab reduced the annualized relapse rate over 2 years by 81 % compared with placebo (0.28 vs. 1.46, respectively; p < 0.001; Table 2 ). In addition, natalizumab reduced the cumulative probability of relapse over 2 years by 75 % (HR = 0.25; CI: 0.16, 0.39; p < 0.001). Significant improvements in other relapse-related endpoints (i. e., relapses requiring steroid therapy and rate of hospitalization) and MRI endpoints were observed with natalizumab compared with placebo (Table 2 ).
In the SENTINEL study, 74 combination-therapy patients and 95 patients receiving IFNβ-1a monotherapy met the criteria for highly active MS despite IFNβ treatment. Demographic and disease characteristics were similar between both treatment groups (data not shown). The mean (SD) age was 36.7 (7.83) years, and the median time since diagnosis was 5 years (range, 1-25). Overall, 74 %, 19 % and 7 % of patients experienced 2, 3 and ≥ 4 relapses, respectively, during the year prior to study entry. The median time since last relapse was 4 months in both treatment groups. These patients with highly active disease in the SENTINEL study had a 2-year cumulative probability of 12-week sustained disability progression of 19 % in the combination therapy group and 40 % in the IFNβ-1a alone group, representing a 61 % reduction in risk of disability progression (HR = 0.39; 95 % CI: 0.21, 0.74; p = 0.004). In addition, combination therapy reduced the 2-year cumulative probability of disability progression sustained for 24 weeks by 58 % (HR = 0.42, CI: 0.19, 0.95; p = 0.038; Fig. 3 b) . The addition of natalizumab to IFNβ-1a reduced the annualized relapse rate over 2 years by 76 % (0.28, combination therapy vs. 1.16, IFNβ-1a alone; p < 0.001; Table 2 ) and the cumulative probability of relapse over 2 years by 66 % (HR = 0.34; CI: 0.22, 0.53; p < 0.001) compared with IFNβ-1a alone. The addition of natalizumab to IFNβ-1a led to significant improvements in other relapse-related and MRI endpoints as well ( 
Discussion
Natalizumab reduced the risk of sustained disability progression (the 2-year primary endpoint) compared with placebo in all subgroups, except for the subgroup of patients with < 9 baseline T2 lesions. The large size of the AFFIRM study and the high level of therapeutic efficacy allowed the detection of statistically significant treatment effects within most subgroups. However, underpowered comparisons in SENTINEL study stemming from a lower number of events in the control arm probably contributed to the nonsignificant treatment effects found in the SENTINEL subgroup analysis. Also, the small sample size in some subgroups (i. e., patients with baseline EDSS scores > 3.5, male patients) probably con- Fig. 3 Kaplan-Meier plots of the 2-year cumulative probability of 24-week sustained progression of disability in the subgroup of patients with highly active relapsing multiple sclerosis in AFFIRM (a) and SENTINEL (b). CI confidence interval; IFNb interferon beta tributed to nonsignificant treatment effects and may have resulted in a type II error. Natalizumab reduced the annualized relapse rate regardless of baseline disease or demographic characteristics, with statistically significant effects observed in both studies in all subgroups except for the small subgroup of patients with < 9 T2 lesions at baseline. Natural history data suggest that the median time from the onset of relapsing MS to secondary progressive MS is approximately 19 years [19] . Confavreux and colleagues identified a number of clinical factors predictive of the onset of irreversible disability: time from MS onset to the second neurological episode, the number of relapses during the first 5 years of disease and time from onset of MS to an EDSS score of 4.0 [17] . Further, Scott and colleagues identified 6 factors that are predictive of poor prognosis: (1) age of onset (≥ 40 years); (2) motor system involvement at onset including weakness of the extremities or ataxia; (3) ≥ 4 T2-weighted lesions suggestive of MS seen on MRI; (4) ≤ 2.5 years between the first 2 relapses; (5) ≥ 2 relapses in the first year of disease; and (6) poor recovery from the initial 2 relapses defined as an EDSS ≥ 1.5 sustained for at least 1 year [14, 20] . Patients with a high number of risk factors (> 3) were Table 3 Comparison of the effects of natalizumab on the overall study population vs. patients with highly active disease more likely to progress to higher EDSS at follow-up. Both these latter studies suggest that by identifying patients at greater risk of EDSS progression, one may determine patients who will derive greater benefit from an effective therapy. Indicators of more active disease early in the clinical course, such as frequent relapses, high T2-lesion load and the presence of Gd+ lesions, have been correlated with a higher risk of disability progression later in the clinical course [15, 16, 21] . Previously, a post hoc analysis of data from a phase 2 study of natalizumab in patients with relapsing MS showed the agent to have the greatest effect in patients with more disease activity [6, 22] . In the post hoc analyses of AFFIRM and SENTINEL presented here, patients with highly active disease reduced annualized relapse rate by 81 % (AFFIRM) and 76 % (SENTI-NEL) and the risk of disability progression by 64 % (AF-FIRM) and 58 % (SENTINEL). Thus natalizumab is effective in patients with highly active disease who require greater treatment efficacy. To this effect, the European Union has indicated natalizumab monotherapy for the treatment of patients with rapidly evolving, severe forms of relapsing MS, regardless of prior treatment [23] . It should be noted that natalizumab is not indicated for patients with primary progressive or secondary progressive MS.
In addition to its beneficial effects in patients with highly active disease, natalizumab also demonstrated efficacy on disability progression and relapse rate in patients with less severe baseline disease (i. e., fewer prestudy relapses, baseline EDSS score ≤ 3.5, no baseline Gd+ lesions). Furthermore, younger patients appeared to benefit more from natalizumab treatment than older patients. There has been a shift in recent years toward early treatment with disease-modifying therapies to reduce the effects of recurrent inflammation and axonal injury, thereby achieving better outcomes [24, 25] . The results of the prespecified subgroup analyses presented herein suggest that treatment with natalizumab is effective early in the disease course. Currently, the use of natalizumab early in the course of MS may be considered if deemed appropriate by the treating physician in the United States or in patients with highly active disease in the European Union [23] .
In patients treated with IFNβ or glatiramer acetate, 62 %-68 % will experience relapses and 20 %-27 % will worsen by ≥ 1 point on the EDSS scale within 2 years [26] [27] [28] [29] . In addition, discontinuation of IFNβ or glatiramer acetate due to side effects or perceived treatment failure is a problem in 14 % of patients with relapsing MS in the first few years of therapy [30, 31] . Such patients may be candidates for switching to natalizumab. Data from the SENTINEL study demonstrate the addition of natalizumab to patients' current IFNβ-1a therapy led to significant reductions in disability progression and relapse rate compared with IFNβ-1a; these effects were most impressive in patients with highly active disease on IFNβ-1a, consistent with the effects observed in treatment-naïve patients. Despite the lack of a monotherapy comparison, it is reasonable to conclude that the significant efficacy effects in the combination group as compared with IFNβ-1a alone were largely driven by natalizumab.
Natalizumab was generally well tolerated in phase 3 clinical studies. The most common adverse events in AF-FIRM were mild and included headache, fatigue, urinary tract infections and arthralgia. Hypersensitivity reactions were observed in less than 1 % of patients treated with natalizumab monotherapy [9] . Progressive multifocal leukoencephalopathy (PML), a rare but serious infection of the central nervous system, occurred in two patients with MS who were also being treated with IFNβ-1a. To mitigate the risk of PML and better evaluate the safety profile of natalizumab, the mandatory Tysabri Outreach: Unified Commitment to Health (TOUCH) Prescribing Program was established in the United States. There have been reports of hepatotoxicity associated with natalizumab in the postmarketing setting, and it is recommended that treatment be withdrawn in patients who develop jaundice or show other signs of liver injury [32] .
In summary, the subgroup analyses presented here confirm and extend those of the primary analyses; natalizumab demonstrated consistent efficacy across subgroups, mostly in patients who were naïve to prior MS therapy but also in those with disease activity on treatment. Based on its efficacy in treatment-naïve patients with highly active disease, natalizumab may be most effective in early actively relapsing MS, when inflammation is a key contributor to the accumulation of disability. As experience with natalizumab increases and its safety profile is further defined, its full potential in the treatment of MS will be determined. 
